One Podium and Two Poster Presentations Will Highlight Pre-Clinical and Clinical Information for Investigational Treatment NOV03, as well as Data from Company’s Unique ARMOR Surveillance Study

VAUGHAN, ON , Sept. 27, 2022 /CNW/ — Bausch + Lomb Corporation (NYSE/TSX: BLCO ) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better,   today announced the presentation of one podium plus two poster presentations at the World Cornea Congress VIII meeting, which will take place in Chicago from Sept. 28-29, 2022 .

The podium presentation will feature findings from the pivotal Phase 3 trials of the particular investigational treatment NOV03 (perfluorohexyloctane), and the poster presentations will include pre-clinical data of NOV03 and data from Bausch + Lomb’s ongoing Antibiotic Resistance Monitoring in Ocular micRoorganisms (ARMOR) surveillance study. The particular ARMOR study is the only continuing surveillance study of its kind that evaluates profiles plus trends in antibiotic resistance among common ocular bacterial pathogens across the United States .

“With the recent FDA acceptance of the New Drug Application for NOV03, we look forward to attending the World Cornea Congress so we can share valuable insights from our NOV03 clinical development program with the ophthalmic community, ” said Christina Ackermann , president, Ophthalmic Pharmaceuticals, Bausch + Lomb. “We will also present findings from our unique ARMOR study, which for more than a decade has helped guide eye care professionals in selecting the most appropriate antibiotic treatment options to meet the particular needs of their patients. ” 

Following is a complete list of titles and lead authors for each of the presentations:

Podium Presentation

• inch NOV03 for the Treatment of Signs and Symptoms of Dry Eye Disease Associated along with Meibomian Gland Dysfunction: GOBI and MOJAVE Study Findings. ” Tauber et al.

Poster Presentations

• inches In Vitro Antibiotic Resistance among Bacterial Pathogens Sourced from the Cornea in ARMOR. ” Asbell  et ing.
• ” In Vitro Studies associated with Perfluorohexyloctane, an Investigational Eye Drop for Dry Vision Disease. very well Borchman et al.

About Bausch + Lomb
Bausch & Lomb is dedicated to protecting plus enhancing typically the gift regarding sight with regard to millions of people around the world – through the moment of birth through every phase involving life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye maintenance systems, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and advancement, manufacturing in addition to commercial footprint with more than 12, 000 employees and a presence in nearly 100 countries. Bausch and up. Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater , New Jersey . For more information, visit  www.bausch.com   and connect with us on Twitter , LinkedIn , Facebook and Instagram .

Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates, micron “hopes, ” “expects, inch “intends, inches “plans, very well “should, micron “could, ” “would, inch “may, inches “believes, very well “estimates, micron “potential, ” “target, inch or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and even uncertainties that could cause actual results in order to differ materially from those described within the forward-looking statements. These types of risks together with uncertainties include, but are not limited to be able to, the risks and additionally uncertainties discussed in Bausch + Lomb’s filings together with the U. S. Securities and Exchange Commission as well as the Canadian Investments Administrators, which usually factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused simply by or relating to this evolving COVID-19 pandemic, and the fear connected with that pandemic and its potential effects, often the severity, duration and future impact with which are usually highly uncertain and cannot be predicted, not to mention which might have a material adverse impact on Bausch + Lomb, including but not limited for you to its project development timelines, launches and also costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking claims. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to help update some of these forward-looking assertions to reflect events or circumstances after the date of this news release or to reveal actual outcomes, unless required by law.

SOURCE Bausch + Lomb Company